Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Recurrent Disease
100%
Patients at Risk
100%
Disease Activity
100%
Remsima
100%
Remicade
100%
Immune-mediated Inflammatory Diseases
50%
Patient-reported Outcomes
37%
Sarcoidosis
37%
Physician Perspective
37%
Illness Perceptions
37%
No Significant Difference
25%
Infliximab
25%
Disease Relapse
25%
Plasma Drug Concentration
25%
Anti-drug Antibodies
25%
Quality of Life
12%
Clinical Assessment
12%
Clinical Practice
12%
Non-infectious
12%
Non-infectious Uveitis
12%
Adverse Events
12%
Disease Activity Score
12%
Therapeutic Efficacy
12%
Monitoring Program
12%
Behet's Disease
12%
Accurate Monitoring
12%
Laboratory Assessment
12%
Safety Monitoring
12%
Significant Disease
12%
High Incidence
12%
Infliximab Biosimilar
12%
Outcome Assessment
12%
Blood Analysis
12%
Anti-tumor Necrosis Factor (anti-TNF)
12%
Laboratory Parameters
12%
Corticosteroid Therapy
12%
Antibody Formation
12%
Routine Blood
12%
Concentration Value
12%
Serious Events
12%
Disease Worsening
12%
Biosimilar
12%
Disease Incidence
12%
Non-difference
12%
Medicine and Dentistry
Recurrent Disease
100%
Infliximab
100%
Observational Study
100%
Disease Activity
100%
Disease
22%
Inflammatory Disorder
22%
Sarcoidosis
16%
Drug Antibody
11%
Infusion
11%
Biosimilar
11%
Quality of Life
5%
Combination Therapy
5%
Clinical Assessment
5%
Tumor Necrosis Factor
5%
Adverse Event
5%
Uveitis
5%
Decision Making
5%
Laboratory Assessment
5%
Corticosteroid Therapy
5%
Biological Product
5%
Blood Analysis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
100%
Recurrent Disease
100%
Observational Study
100%
Disease Activity
100%
Disease
22%
Inflammatory Disease
22%
Sarcoidosis
16%
Drug Antibody
11%
Biosimilar Agent
11%
Drug Concentration
11%
Uveitis
5%
Tumor Necrosis Factor
5%
Adverse Event
5%
Biological Product
5%
Combination Therapy
5%
Immunology and Microbiology
Infliximab
100%
Immune-Mediated Inflammatory Diseases
22%
Sarcoidosis
16%
Biosimilar Agent
11%
Drug Concentration
11%
Drug Antibody
11%
Tumor Necrosis Factor Alpha
5%
Uveitis
5%
Biological Product
5%
Decision Making
5%